We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.
Quote | Fortress Biotech Inc. (NASDAQ:FBIO)
Last: | $1.715 |
---|---|
Change Percent: | -4.19% |
Open: | $1.75 |
Close: | $1.79 |
High: | $1.77 |
Low: | $1.66 |
Volume: | 185,697 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Fortress Biotech Inc. (NASDAQ:FBIO)
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (...
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...
Message Board Posts | Fortress Biotech Inc. (NASDAQ:FBIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $FBIO News Article - Checkpoint Therapeutics Announces $6.1 Million Registered Direct O | whytestocks | investorshangout | 03/31/2023 5:40:56 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation Reports Full-Year 2022 Financial Resul | whytestocks | investorshangout | 03/29/2023 8:26:10 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation to Participate in the 35th Annual ROTH | whytestocks | investorshangout | 03/07/2023 6:35:47 PM |
Has $FBIO gotten a NASDAQ warning letter yet? | Spicknspan | investorshub | 02/28/2023 12:20:02 AM |
whytestocks: $FBIO News Article - Helocyte, Inc. Announces Positive Data from Stem Cell Transplant D | whytestocks | investorshangout | 02/16/2023 7:40:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Fortress Biotech Inc. Company Name:
FBIO Stock Symbol:
NASDAQ Market:
Fortress Biotech Inc. Website:
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commerci...
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (...
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...